These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 15206107)

  • 21. Is matching ruthenium with dithiocarbamato ligands a potent chemotherapeutic weapon in oncology?
    Nardon C; Brustolin L; Fregona D
    Future Med Chem; 2016; 8(2):211-26. PubMed ID: 26807601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Photostability profiles of the experimental antimetastatic ruthenium complex NAMI-A.
    Bouma M; Nuijen B; Jansen MT; Sava G; Bult A; Beijnen JH
    J Pharm Biomed Anal; 2002 Nov; 30(4):1287-96. PubMed ID: 12408919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of anticancer role of a novel ruthenium(II)-based compound compared with NAMI-A and cisplatin in impairing mitochondrial functionality and promoting oxidative stress in triple negative breast cancer models.
    Silvestri S; Cirilli I; Marcheggiani F; Dludla P; Lupidi G; Pettinari R; Marchetti F; Di Nicola C; Falcioni G; Marchini C; Orlando P; Tiano L; Amici A
    Mitochondrion; 2021 Jan; 56():25-34. PubMed ID: 33220497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Organometallic ruthenium inhibitors of glutathione-S-transferase P1-1 as anticancer drugs.
    Ang WH; De Luca A; Chapuis-Bernasconi C; Juillerat-Jeanneret L; Lo Bello M; Dyson PJ
    ChemMedChem; 2007 Dec; 2(12):1799-806. PubMed ID: 17918761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fate of the antimetastatic ruthenium complex ImH [trans-RuCl4(DMSO)Im] after acute i.v. treatment in mice.
    Cocchietto M; Salerno G; Alessio E; Mestroni G; Sava G
    Anticancer Res; 2000; 20(1A):197-202. PubMed ID: 10769655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmaceutical development of a parenteral lyophilized formulation of the antimetastatic ruthenium complex NAMI-A.
    Bouma M; Nuijen B; Sava G; Perbellini A; Flaibani A; van Steenbergen MJ; Talsma H; Kettenes-van den Bosch JJ; Bult A; Beijnen JH
    Int J Pharm; 2002 Nov; 248(1-2):247-59. PubMed ID: 12429478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined therapy of the antimetastatic compound NAMI-A and electroporation on B16F1 tumour cells in vitro.
    Bicek A; Turel I; Kanduser M; Miklavcic D
    Bioelectrochemistry; 2007 Nov; 71(2):113-7. PubMed ID: 17602896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and antiproliferative activity.
    Groessl M; Reisner E; Hartinger CG; Eichinger R; Semenova O; Timerbaev AR; Jakupec MA; Arion VB; Keppler BK
    J Med Chem; 2007 May; 50(9):2185-93. PubMed ID: 17402720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ruthenium anticancer drugs and proteins: a study of the interactions of the ruthenium(III) complex imidazolium trans-[tetrachloro(dimethyl sulfoxide)(imidazole)ruthenate(III)] with hen egg white lysozyme and horse heart cytochrome c.
    Casini A; Mastrobuoni G; Terenghi M; Gabbiani C; Monzani E; Moneti G; Casella L; Messori L
    J Biol Inorg Chem; 2007 Nov; 12(8):1107-17. PubMed ID: 17680283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biophysical characterisation of adducts formed between anticancer metallodrugs and selected proteins: new insights from X-ray diffraction and mass spectrometry studies.
    Casini A; Guerri A; Gabbiani C; Messori L
    J Inorg Biochem; 2008; 102(5-6):995-1006. PubMed ID: 18289690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of the anionic ligands on the anticancer activity of Ru(II)-dmso complexes: Kinetics of aquation and in vitro cytotoxicity of new dicarboxylate compounds in comparison with their chloride precursors.
    Bratsos I; Bergamo A; Sava G; Gianferrara T; Zangrando E; Alessio E
    J Inorg Biochem; 2008 Apr; 102(4):606-17. PubMed ID: 18063052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NAMI-A is highly cytotoxic toward leukaemia cell lines: evidence of inhibition of KCa 3.1 channels.
    Pillozzi S; Gasparoli L; Stefanini M; Ristori M; D'Amico M; Alessio E; Scaletti F; Becchetti A; Arcangeli A; Messori L
    Dalton Trans; 2014 Aug; 43(32):12150-5. PubMed ID: 24975719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ruthenium-based compounds and tumour growth control (review).
    Sava G; Bergamo A
    Int J Oncol; 2000 Aug; 17(2):353-65. PubMed ID: 10891547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A.
    Vacca A; Bruno M; Boccarelli A; Coluccia M; Ribatti D; Bergamo A; Garbisa S; Sartor L; Sava G
    Br J Cancer; 2002 Mar; 86(6):993-8. PubMed ID: 11953835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An all-inorganic, stable, and highly active tetraruthenium homogeneous catalyst for water oxidation.
    Geletii YV; Botar B; Kögerler P; Hillesheim DA; Musaev DG; Hill CL
    Angew Chem Int Ed Engl; 2008; 47(21):3896-9. PubMed ID: 18351608
    [No Abstract]   [Full Text] [Related]  

  • 36. Cocultures of metastatic and host immune cells: selective effects of NAMI-A for tumor cells.
    Bacac M; Vadori M; Sava G; Pacor S
    Cancer Immunol Immunother; 2004 Dec; 53(12):1101-10. PubMed ID: 15221285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumour cell uptake of the metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells.
    Frausin F; Cocchietto M; Bergamo A; Scarcia V; Furlani A; Sava G
    Cancer Chemother Pharmacol; 2002 Nov; 50(5):405-11. PubMed ID: 12439599
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Actin-dependent tumour cell adhesion after short-term exposure to the antimetastasis ruthenium complex NAMI-A.
    Sava G; Frausin F; Cocchietto M; Vita F; Podda E; Spessotto P; Furlani A; Scarcia V; Zabucchi G
    Eur J Cancer; 2004 Jun; 40(9):1383-96. PubMed ID: 15177498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of cisplatin and NAMI-A plasma-protein interactions in relation to combination therapy.
    Khalaila I; Bergamo A; Bussy F; Sava G; Dyson PJ
    Int J Oncol; 2006 Jul; 29(1):261-8. PubMed ID: 16773208
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strategy to tether organometallic ruthenium-arene anticancer compounds to recombinant human serum albumin.
    Ang WH; Daldini E; Juillerat-Jeanneret L; Dyson PJ
    Inorg Chem; 2007 Oct; 46(22):9048-50. PubMed ID: 17918830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.